RNAi Roundtable: Cemdisiran, in Development for the Treatment of IgA Nephropathy (IgAN) and Other Complement-Mediated Diseases

27 Sep, 2022 RNAi Roundtable: Cemdisiran, in Development for the Treatment of IgA Nephropathy (IgAN) and Other Complement-Mediated Diseases

On September 27, 2022, we hosted an online RNAi Roundtable to review the progress with cemdisiran, an investigational RNAi therapeutic in development for the treatment of IgA nephropathy (IgAN) and other complement-mediated diseases.

Access the replay
View the presentation

Eric Green
Senior Vice President, Development Programs

Sonalee Agarwal, Ph.D.
Vice President and Program Leader, Cemdisiran

Jonathan Barratt, Ph.D., FRCP
The Mayer Professor of Renal Medicine Department of Cardiovascular Sciences; Honorary Consultant Nephrologist, The John Walls Renal Unit, Leicester General Hospital

Ishir Bhan, M.D., MPH
Senior Director, Clinical Research